{
    "organizations": [],
    "uuid": "2c37ed736a1a0d7a2ffa80e6c4afb2c2295c7ac3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-eylea-injection-demonstrates-posit/brief-eylea-injection-demonstrates-positive-topline-results-in-phase-3-non-proliferative-diabetic-retinopathy-trial-idUSASC09SQW",
    "ord_in_thread": 0,
    "title": "BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 14 AM / Updated 11 minutes ago BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial Reuters Staff March 19 (Reuters) - Regeneron Pharmaceuticals Inc: * EYLEAÂ® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL * REGENERON PHARMA-PHASE 3 TRIAL EVALUATING EYLEA INJECTION IN MODERATELY SEVERE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY MET PRIMARY ENDPOINT * REGENERON PHARMA - 58 PERCENT OF EYLEA-TREATED PATIENTS EXPERIENCED TWO-STEP OR GREATER IMPROVEMENT FROM BASELINE ON DIABETIC RETINOPATHY SEVERITY SCALE (DRSS) AT WEEK 24 * REGENERON PHARMACEUTICALS INC - THERE WAS ONE CASE OF MILD INTRAOCULAR INFLAMMATION (IOI) IN A PATIENT TREATED WITH EYLEA IN TRIAL * REGENERON PHARMACEUTICALS - EXPECT U.S. REGULATORY SUBMISSION FOR DIABETIC RETINOPATHY LATER THIS YEAR Source text for Eikon:  ",
    "published": "2018-03-19T13:14:00.000+02:00",
    "crawled": "2018-03-19T13:27:52.079+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "aflibercept",
        "injection",
        "demonstrates",
        "positive",
        "topline",
        "result",
        "phase",
        "diabetic",
        "retinopathy",
        "trial",
        "reuters",
        "staff",
        "march",
        "reuters",
        "regeneron",
        "pharmaceutical",
        "inc",
        "aflibercept",
        "injection",
        "demonstrates",
        "positive",
        "topline",
        "result",
        "phase",
        "diabetic",
        "retinopathy",
        "trial",
        "regeneron",
        "trial",
        "evaluating",
        "eylea",
        "injection",
        "moderately",
        "severe",
        "severe",
        "diabetic",
        "retinopathy",
        "met",
        "primary",
        "endpoint",
        "regeneron",
        "pharma",
        "percent",
        "patient",
        "experienced",
        "greater",
        "improvement",
        "baseline",
        "diabetic",
        "retinopathy",
        "severity",
        "scale",
        "drss",
        "week",
        "regeneron",
        "pharmaceutical",
        "inc",
        "one",
        "case",
        "mild",
        "intraocular",
        "inflammation",
        "ioi",
        "patient",
        "treated",
        "eylea",
        "trial",
        "regeneron",
        "pharmaceutical",
        "expect",
        "regulatory",
        "submission",
        "diabetic",
        "retinopathy",
        "later",
        "year",
        "source",
        "text",
        "eikon"
    ]
}